 |
|
Effective treatment for sickle cell underused by doctors
June 18, 2008Uncertainties about proper use and possible long-term effects of hydroxyurea in the treatment of sickle cell anemia may be wrongly influencing doctors to avoid prescribing it to those in serious need, according to results of a literature review by specialists at Johns Hopkins.
"We know that many people with sickle cell disease aren't being offered this drug, which is the only one we have to treat this disease," says Sophie Lanzkron, M.D., assistant professor of medicine and oncology at the Johns Hopkins University School of Medicine and director of the Sickle Cell Center for Adults at Johns Hopkins.
In a bid to heighten awareness about the nature of the uncertainties and correct clinical use of the drug, the U.S. Department of Health and Human Services selected Lanzkron and her colleagues at Johns Hopkins to gather information from previously published studies on hydroxyurea.
First, they combed through databases to select randomized clinical trials, observational studies and case reports that evaluated the drug's effectiveness and incidences of toxic side effects. They excluded the poorer quality data and non-English publications and carefully analyzed data from 246 articles.
What emerged, the researchers say, is a clear picture of the drug's effectiveness.
Specifically, they found that the number of intensely painful sickle cell "crises," caused when misshapen, "sickled" red blood cells clump in blood vessels, dropped by 68 to 84 percent in people taking hydroxyurea. Their hospital admissions declined by 18 to 32 percent.
On the biological side, amounts of fetal hemoglobin, a blood component that seems to decrease sickle cell symptoms, increased by 4 to 20 percent after patients began taking hydroxyurea.
On the negative side of the risk/benefit ledger, studies in mice also indicated that hydroxyurea impairs sperm development. The researchers concluded that this effect could be present in human patients as well. The review could not conclude with any confidence that hydroxyurea increased or decreased the risk of leukemia or other tumors, leg ulcers and pregnancy complications.
In the team's report, published in the June 17 Annals of Internal Medicine, they conclude that hydroxyurea be considered a viable treatment option, but emphasized the need for more quality research.
"It's clear from our literature review that hydroxyurea works, but we need to do much more work to understand how it works and the best ways to use it," Lanzkron says.
Sickle cell anemia, an inherited disorder that affects mostly people of African and Hispanic heritage, is named for the crescent- or sickle-shaped blood cells caused by the disease. The C-shaped cells periodically clump inside blood vessels, blocking circulation and causing severe anemia, increased risk of infections or strokes, and episodes of extreme pain that can last hours or days. About 70,000 people have sickle cell disease in the United States.
Johns Hopkins Medical Institutions
First, they combed through databases to select randomized clinical trials, observational studies and case reports that evaluated the drug's effectiveness and incidences of toxic side effects. They excluded the poorer quality data and non-English publications and carefully analyzed data from 246 articles.
What emerged, the researchers say, is a clear picture of the drug's effectiveness.
Specifically, they found that the number of intensely painful sickle cell "crises," caused when misshapen, "sickled" red blood cells clump in blood vessels, dropped by 68 to 84 percent in people taking hydroxyurea. Their hospital admissions declined by 18 to 32 percent.
On the biological side, amounts of fetal hemoglobin, a blood component that seems to decrease sickle cell symptoms, increased by 4 to 20 percent after patients began taking hydroxyurea.
On the negative side of the risk/benefit ledger, studies in mice also indicated that hydroxyurea impairs sperm development. The researchers concluded that this effect could be present in human patients as well. The review could not conclude with any confidence that hydroxyurea increased or decreased the risk of leukemia or other tumors, leg ulcers and pregnancy complications.
In the team's report, published in the June 17 Annals of Internal Medicine, they conclude that hydroxyurea be considered a viable treatment option, but emphasized the need for more quality research.
"It's clear from our literature review that hydroxyurea works, but we need to do much more work to understand how it works and the best ways to use it," Lanzkron says.
Sickle cell anemia, an inherited disorder that affects mostly people of African and Hispanic heritage, is named for the crescent- or sickle-shaped blood cells caused by the disease. The C-shaped cells periodically clump inside blood vessels, blocking circulation and causing severe anemia, increased risk of infections or strokes, and episodes of extreme pain that can last hours or days. About 70,000 people have sickle cell disease in the United States.
Johns Hopkins Medical Institutions
Sickle Cell News and Current Sickle Cell Events RSSChildren's national co-leads nationwide study of landmark sickle cell treatment
Children's National Medical Center immunologist and blood and marrow transplant physician Naynesh Kamani, MD, will serve as the study co-chair for a new national clinical trial of unrelated donor marrow and umbilical cord blood transplants for severe sickle cell disease.
Most generalists reluctant to provide primary care for young adults with chronic illness
The majority of general internists and pediatricians in the United States are not comfortable serving as primary care providers for young adults with complex chronic illnesses that originate during childhood, according to findings from a new national survey.
Consortium develops new method to manipulate genetic material
A multi-institutional team of researchers, including scientists at the University of Minnesota Medical School, have developed a powerful tool for genomic research and medicine.
Gaining ground on sickle cell disease
Although sickle cell disease is a single-gene disorder, its symptoms are highly variable. In a study published online July 14 by the Proceedings of the National Academy of Sciences, scientists at Children's Hospital Boston and the Dana Farber Cancer Institute (DFCI), in collaboration with the Broad Institute of MIT and Harvard, report five gene variants that could potentially be helpful in predicting sickle cell disease severity, perhaps even leading to better treatment approaches in the future.
Statistical tool could explain gene study variations
While scientists are using the human genome to associate certain genes with disease, Dr. Hongyan Xu wants to ensure they are accounting for natural variations in those genes.
Major 'missed' biochemical pathway emerges as important in virtually all cells
A new study by Duke University researchers provides more evidence that the nitric oxide (NO) system in the life of a cell plays a key role in disease, and the findings point to ways to improve treatment of illnesses such as heart disease and cancer.
For children with sickle cell disease, lung disease is part of the package
Children with sickle cell disease (SCD) have a significantly sharper decline in lung function with age when compared to other children of the same race and age.
Clumps of red and white blood cells may contribute to sickle cell disease
It's long been known that patients with sickle cell disease have malformed, "sickle-shaped" red blood cells - which are normally disc-shaped - that can cause sudden painful episodes when they block small blood vessels.
Researchers at UCLA engineering discover theoretical model to predict jamming
Researchers at the UCLA Henry Samueli School of Engineering and Applied Science have come up with a theoretical model to predict when granular materials become jammed.
New stem cell technique improves genetic alteration
UC Irvine researchers have discovered a dramatically improved method for genetically manipulating human embryonic stem cells, making it easier for scientists to study and potentially treat thousands of disorders ranging from Huntington's disease to muscular dystrophy and diabetes.
More Sickle Cell News Articles
 | The Troubled Dream of Genetic Medicine: Ethnicity and Innovation in Tay-Sachs, Cystic Fibrosis, and Sickle Cell Disease by Keith Wailoo, Stephen Pemberton Why do racial and ethnic controversies become attached, as they often do, to discussions of modern genetics? How do theories about genetic difference become entangled with political debates about cultural and group differences in America? Such issues are a conspicuous part of the histories of three hereditary diseases: Tay-Sachs, commonly identified with Jewish Americans; cystic fibrosis, often... |
 | Comprehensive Handbook of Childhood Cancer and Sickle Cell Disease: A Biopsychosocial Approach Over recent decades, tremendous advances in the prevention, medical treatment, and quality of life issues in children and adolescents surviving cancer have spawned a host of research on pediatric psychosocial oncology. This important volume fulfills the clear need for an up-to-date, comprehensive handbook for practitioners that delineates the most recent research in the field--the first of its... |
 | Dying in the City of the Blues: Sickle Cell Anemia and the Politics of Race and Health by Keith Wailoo This history of the recognition, research, and treatment of sickle cell anemia provides important insight into the African American experience, race relations, and the politics of science, medicine, and... |
 | Hope and Destiny: A Patient's and Parent's Guide to Sickle Cell Anemia by Allan F. Platt, Alan Sacerdote For anyone who has or is predisposed to sickle cell disease, this informative and compassionate guide provides all the facts patients, loved ones, and caregivers need to know in order to reduce symptoms, relieve pain, and help patients and their support circle better understand the cause and growth of the disease. Divided into different sections to address the changing complications posed by the... |
 | Ecobeaker Computer Labs for Explorations in Ecology and Evolution by Eli Meir Two ring binder pamplets included in this package. One is Student Workbook for Sickle-cell Alleles. The 2nd is Student workbook for... |
 | Race And Medicine in Nineteenth-and Early-Twentieth-century America by Todd L. Savitt |
 | Raffi's Animal Rescue (Formac First Novels) by Sylvain Meunier Raffi McCaffrey can't move the way most kids can. He has a condition that makes it hard for him to get around. So, he spends a lot of time at his window watching the birds. One morning, when he is studying the trees outside his window, he suddenly sees something move. It's a bird -- and it's injured! Its wing is hurt and it can't fly any more. What can Raffi do to save the bird? In this story... |
| A SYLLABUS OF HUMAN HEMOGLOBIN VARIANTS (2ND EDITION) by MARIANNE F.H. CARVER, GEORGI D. EFREMOV TITUS H.J. HUISMAN | |
| The management of sickle cell disease | |
 | Disorders of Hemoglobin: Genetics, Pathophysiology and Clinical Management Disorders of Hemoglobin is the first comprehensive reference on the genetic and acquired disorders of hemoglobin in over a decade. It stands as the definitive work on the genetics, pathophysiology, and clinical management of this wide range of disorders. Drs. Steinberg, Forget, Higgs, and Nagel have gathered the absolute world authorities on the science and clinical management of thalassemias,... |
| © 2008 BrightSurf.com |